Lacosamide Teva

Lacosamide, the active ingredient in Lacosamide Teva, is an anti‑epileptic presented as an oral dosage form for oral use. It treats partial‑onset seizures in patients with epilepsy and is prescribed as part of a broader seizure‑control regimen.

GNH USA supplies Lacosamide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity. It is indicated for the following conditions: - Partial‑onset seizures: reduces the frequency and severity of focal seizures. - Epilepsy (adjunctive therapy): provides additional seizure control when combined with other antiepileptic drugs. - Focal epilepsy: targets focal seizure activity to improve overall patient outcomes.

Lacosamide may cause a range of adverse reactions, from mild to serious. Monitoring and reporting of side effects are essential for safe use.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate gastrointestinal upset. - Headache: recurrent or persistent head pain. - Fatigue: increased tiredness or lack of energy.

Serious or Rare Side Effects: - Cardiac arrhythmia: abnormal heart rhythm, especially PR‑interval prolongation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.

Before initiating therapy, clinicians should consider several safety factors to minimize risk. - Renal impairment: assess kidney function and adjust monitoring as needed. - Hepatic dysfunction: use with caution in patients with liver disease. - Cardiac conduction abnormalities: obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: risk category unknown; discuss potential benefits and risks with the patient. - Concomitant CNS depressants: may increase dizziness or somnolence. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Lacosamide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce lacosamide plasma levels. - Other sodium‑channel blockers (e.g., phenytoin): increase risk of central nervous system adverse effects.

Moderate Interactions (Monitor Closely): - Carbamazepine: may raise lacosamide concentrations. - Anticoagulants (e.g., warfarin): potential impact on bleeding risk. - Alcohol: can enhance dizziness and sedation.